Evidence indicates that patients with advanced-stage cutaneous T cell lymphomas (CTCLs) might benefit from allogeneic haematopoietic stem-cell transplantation (HSCT); however, the data come from single-arm, mostly retrospective case series. Now, results from the prospective, controlled CUTALLO study confirm that HSCT improves outcomes.